CDT Equity Secures $1.46M Loan, Repays $6.3M Debt, and Restructures Balance Sheet
Summary
CDT Equity Inc. secured a new $1.46 million convertible loan, enabling the repayment of over $6.3 million in legacy debt for a net reduction of $4.83 million, significantly restructuring its balance sheet and addressing going concern issues.
Key Events
-
Major Debt Restructuring
The company secured a new $1.46 million senior secured convertible promissory note from J.J. Astor & Co. This enabled the repayment of a $5.74 million convertible loan note with A.G.P. and a $0.56 million promissory note with Ascent Partners, resulting in a net debt reduction of approximately $4.83 million.
-
New Convertible Note and Warrants Issued
The $1.97 million principal amount note (from which $1.46 million was received) is convertible by the lender at 90% of the lowest 10-day VWAP or Nasdaq floor price after six months. In case of default, the outstanding amount increases by 20% and accrues 19% interest, with a conversion price of 70% of the lowest 20-day VWAP or floor price. Warrants to purchase 912,500 shares at an exercise price of $0.72 per share were also issued, exercisable upon stockholder approval.
-
Nasdaq Compliance Covenants
The loan agreement includes covenants requiring the company to cure its Nasdaq deficiency for failing to file its Q1 2026 10-Q within 30 days and to maintain its Nasdaq listing, directly addressing recent compliance issues.
-
ATM Proceeds Allocated to Debt Repayment
80% of the net proceeds from the company's existing At-The-Market (ATM) equity offering program will be used to pay down the weekly installments of the new note, and 50% thereafter until the note is fully satisfied.
Analysis
CDT Equity Inc., a company previously flagged with a 'going concern' warning, has significantly restructured its balance sheet by securing a new $1.46 million senior secured convertible promissory note for working capital. Crucially, this new financing facilitated the repayment of over $6.3 million in legacy debt, resulting in a net debt reduction of approximately $4.83 million. This substantial debt reduction, representing over 138% of the company's current market capitalization, is a critical step towards addressing its financial distress and extending its operational runway. The agreement also includes covenants to cure a Nasdaq deficiency related to overdue filings, directly addressing compliance risks. While the new note and associated warrants introduce potential future dilution through convertible shares and warrants, the immediate benefit of debt reduction and securing vital capital for a distressed company is a strong positive for its continued operations.
At the time of this filing, CDT was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.67 to $610.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.